Originally published Aug. 27.

UK-based personalized medicine firm Lab21 will be offering analysis of the CES-1 gene, which has been shown in studies to influence the metabolism of a number of commonly prescribed drugs in people who harbor mutations in this gene.

Lab21 this week said that it has taken a global license from the Medical University of South Carolina's Foundation for Research Development allowing for the detection and analysis of genetic variants of the human carboxylesterase-1 gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.